Doxylamine

Generic name: Pronounced as (dox il' a meen)
Brand names
  • Aldex AN®
  • Nighttime Sleep Aid
  • Unisom® SleepTabs
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 07/15/2018

Doxylamine is used in the short-term treatment of insomnia (difficulty falling asleep or staying asleep). Doxylamine is also used in combination with decongestants and other medications to relieve sneezing, runny nose, and nasal congestion caused by the common cold. Doxylamine should not be used to cause sleepiness in children. Doxylamine is in a class of medications called antihistamines. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms.

Doxylamine comes as a tablet to take by mouth for sleep, and in combination with other medications as a liquid and liquid-filled capsule to treat symptoms of the common cold. When doxylamine is used to reduce difficulty falling asleep, it usually is taken 30 minutes before bedtime. When doxylamine is used to treat cold symptoms, it is usually taken every 4 to 6 hours. Follow the directions on the package label or on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take doxylamine exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor or directed on the package label.

Doxylamine comes alone and in combination with pain relievers, fever reducers, and cough suppressants, If you are choosing a product to treat cough or cold symptoms, ask your doctor or pharmacist for advice on which product is best for your symptoms. Check nonprescription cough and cold product labels carefully before using two or more products at the same time. These products may contain the same active ingredient(s) and taking them together could cause you to receive an overdose.

Nonprescription cough and cold combination products, including products that contain doxylamine, can cause serious side effects or death in young children. Do not give nonprescription products that contain doxylamine to children younger than 4 years of age. Ask a doctor before giving these products to children 4 to 12 years of age.

Cough and cold symptoms that get worse or that do not go away may be signs of a more serious condition. If you are taking doxylamine in combination with other medications to treat cough and cold symptoms, call your doctor if your symptoms worsen or if they last longer than 7 days.

If you are taking doxylamine to treat insomnia, you will probably become very sleepy soon after you take the medication and will remain sleepy for some time after you take the medication. Plan to remain asleep for 7 to 8 hours after taking the medication. If you get up too soon after taking doxylamine, you may be drowsy.

Doxylamine should only be used to treat insomnia for a short time. Call your doctor if you feel that you need to take doxylamine for longer than 2 weeks.

If you are using the liquid, do not use a household spoon to measure your dose. Use the measuring cup or spoon that came with the medication or use a spoon that is made especially for measuring medication.

This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.

Before taking doxylamine,

  • tell your doctor and pharmacist if you are allergic to doxylamine, any other medications, or any of the ingredients in the doxylamine preparation. Ask your doctor or pharmacist or check the package label for a list of the ingredients.

  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: medications for colds, hay fever, or allergies; medications for depression; muscle relaxants; narcotic medications for pain; sedatives; sleep medications; and tranquilizers.

  • tell your doctor if you have or have ever had asthma, emphysema, chronic bronchitis, or other breathing problems; glaucoma (a condition in which increased pressure in the eye can lead to gradual loss of vision); ulcers; difficulty urinating (due to an enlarged prostate gland); heart disease, high blood pressure, seizures,or an overactive thyroid gland.

  • tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking doxylamine, call your doctor.

  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking doxylamine.

  • you should know that this medication may make you drowsy. Do not drive a car or operate machinery until you know how this medication affects you.

  • remember that alcohol can add to the drowsiness caused by this medication. Avoid alcoholic beverages while you are taking this medication.

  • talk to your doctor about the risks and benefits of taking doxylamine if you are 65 years of age or older. Older adults should not usually take doxylamine because it is not as safe or effective as other medications that can be used to treat the same condition.

Unless your doctor tells you otherwise, continue your normal diet.

Doxylamine is usually taken as needed. If your doctor has told you to take doxylamine regularly, take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

  • Doxylamine may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • dry mouth, nose, and throat

    • drowsiness

    • nausea

    • increased chest congestion

    • headache

    • excitement

    • nervousness

  • Some side effects can be serious. If you experience any of the following symptoms, call your doctor immediately:

    • vision problems

    • difficulty urinating

  • Doxylamine may cause other side effects. Call your doctor if you have any unusual problems while you are taking this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Ask your pharmacist any questions you have about doxylamine.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

  • Alka-Seltzer Plus® Night Cold Formula (containing Aspirin, Dextromethorphan, Doxylamine, Phenylephrine)
  • Coricidin® HBP Nighttime Multi-Symptom Cold (containing Acetaminophen, Dextromethorphan, Doxylamine)
  • Tylenol® Cold and Cough Nighttime (containing Acetaminophen, Dextromethorphan, Doxylamine)
  • Vicks NyQuil® Cold and Flu Relief (containing Acetaminophen, Dextromethorphan, Doxylamine)
  • Vicks NyQuil® Cold and Flu Symptom Relief Plus Vitamin C (containing Acetaminophen, Dextromethorphan, Doxylamine)
  • Vicks NyQuil® Cough (containing Dextromethorphan, Doxylamine)
  • Vicks NyQuil® Sinex Nighttime Sinus Relief (containing Acetaminophen, Doxylamine, Phenylephrine)
  • Zicam® Multi-Symptom Cold and Flu Nighttime (containing Acetaminophen, Dextromethorphan, Doxylamine)

Drug Interaction
Moxifloxacin Moxifloxacin The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Moxifloxacin.
Dolasetron Dolasetron Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dolasetron.
Anagrelide Anagrelide The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Anagrelide.
Bisacodyl Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Doxylamine.
Cilostazol Cilostazol The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Cilostazol.
Diphenoxylate Diphenoxylate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Erythromycin.
Guanfacine Guanfacine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.
Magnesium Hydroxide Magnesium Hydroxide The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Doxylamine.
Magnesium Oxide Magnesium Oxide The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Doxylamine.
Naratriptan Naratriptan Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Naratriptan.
Paregoric Paregoric Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Morphine.
Penbutolol Penbutolol The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Acebutolol.
Pentazocine Pentazocine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.
Polyethylene glycol-electrolyte solution (PEG-ES) Polyethylene glycol-electrolyte solution (PEG-ES) The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Doxylamine.
Psyllium Psyllium The therapeutic efficacy of Plantago seed can be decreased when used in combination with Doxylamine.
Reserpine Reserpine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Reserpine.
Rizatriptan Rizatriptan Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Rizatriptan.
Sumatriptan Sumatriptan Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sumatriptan.
Tacrolimus Tacrolimus The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Tacrolimus.
Tizanidine Tizanidine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.
Zolmitriptan Zolmitriptan Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zolmitriptan.
Famotidine Injection Famotidine Injection The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Famotidine.
Fluconazole Injection Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Doxylamine.
Foscarnet Injection Foscarnet Injection The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Foscarnet.
Hydromorphone Injection Hydromorphone Injection Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.
Levofloxacin Injection Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Levofloxacin.
Meperidine Injection Meperidine Injection Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Meperidine.
Metoclopramide Injection Metoclopramide Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Doxylamine.
Metronidazole Injection Metronidazole Injection The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Metronidazole.
Morphine Injection Morphine Injection Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Morphine.
Altretamine Altretamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Amphetamine.
Ondansetron Ondansetron Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.
Granisetron Granisetron Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Granisetron.
Olanzapine Olanzapine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
Alosetron Alosetron Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Alosetron.
Dofetilide Dofetilide The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Dofetilide.
Entacapone Entacapone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Entacapone.
Hydroxychloroquine Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Hydroxychloroquine.
Oxcarbazepine Oxcarbazepine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxcarbazepine.
Zaleplon Zaleplon Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
Desloratadine Desloratadine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.
Linezolid Linezolid Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Linezolid.
Rivastigmine Rivastigmine The therapeutic efficacy of Doxylamine can be decreased when used in combination with Rivastigmine.
Trimipramine Trimipramine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
Glycopyrrolate Glycopyrrolate The risk or severity of adverse effects can be increased when Doxylamine is combined with Glycopyrronium.
Epinephrine Injection Epinephrine Injection The therapeutic efficacy of Epinephrine can be increased when used in combination with Doxylamine.
Escitalopram Escitalopram Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Escitalopram.
Zonisamide Zonisamide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.
Aripiprazole Aripiprazole Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
Atomoxetine Atomoxetine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Atomoxetine.
Dexmethylphenidate Dexmethylphenidate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dexmethylphenidate.
Atazanavir Atazanavir The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Atazanavir.
Almotriptan Almotriptan Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Almotriptan.
Eletriptan Eletriptan Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Eletriptan.
Mefloquine Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Doxylamine.
Polyethylene Glycol 3350 Polyethylene Glycol 3350 The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Doxylamine.
Vardenafil Vardenafil The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Vardenafil.
Alfuzosin Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Doxylamine.
Memantine Memantine The therapeutic efficacy of Doxylamine can be decreased when used in combination with Memantine.
Tegaserod Tegaserod The therapeutic efficacy of Tegaserod can be decreased when used in combination with Doxylamine.
Frovatriptan Frovatriptan Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Frovatriptan.
Gemifloxacin Gemifloxacin The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Gemifloxacin.
Apomorphine Injection Apomorphine Injection Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Apomorphine.
Protriptyline Protriptyline Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.
Duloxetine Duloxetine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Duloxetine.
Trospium Trospium Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Trospium.
Erlotinib Erlotinib The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Erlotinib.
Eszopiclone Eszopiclone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.
Solifenacin Solifenacin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.
Voriconazole Voriconazole The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Voriconazole.
Dextroamphetamine Dextroamphetamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Amphetamine.
Pramlintide Injection Pramlintide Injection The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Doxylamine.
Sodium Oxybate Sodium Oxybate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Ibandronate Ibandronate The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ibandronate.
Isocarboxazid Isocarboxazid Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Isocarboxazid.
Ramelteon Ramelteon Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.
Darifenacin Darifenacin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.
Fentanyl Fentanyl Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.
Pregabalin Pregabalin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.
Felbamate Felbamate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
Ranolazine Ranolazine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ranolazine.
Rasagiline Rasagiline Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Rasagiline.
Imatinib Imatinib The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Imatinib.
Albuterol Albuterol The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Salbutamol.
Paliperidone Paliperidone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
Bortezomib Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Doxylamine.
Lubiprostone Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Doxylamine.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Oxaliplatin.
Posaconazole Posaconazole The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Posaconazole.
Primaquine Primaquine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Primaquine.
Dimenhydrinate Dimenhydrinate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
Lisdexamfetamine Lisdexamfetamine Lisdexamfetamine may decrease the sedative and stimulatory activities of Doxylamine.
Nabilone Nabilone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nabilone.
Vorinostat Vorinostat The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Vorinostat.
Sorafenib Sorafenib The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Sorafenib.
Sunitinib Sunitinib The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Sunitinib.
Dronabinol Dronabinol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dronabinol.
Lapatinib Lapatinib The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Lapatinib.
Levocetirizine Levocetirizine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.
Dasatinib Dasatinib The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Dasatinib.
Paclitaxel (with polyoxyethylated castor oil) Injection Paclitaxel (with polyoxyethylated castor oil) Injection The therapeutic efficacy of Castor oil can be decreased when used in combination with Doxylamine.
Nilotinib Nilotinib The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Nilotinib.
Toremifene Toremifene The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Toremifene.
Betaine Betaine The therapeutic efficacy of Doxylamine can be decreased when used in combination with Glycine betaine.
OnabotulinumtoxinA Injection OnabotulinumtoxinA Injection Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.
RimabotulinumtoxinB Injection RimabotulinumtoxinB Injection Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type B.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Arsenic trioxide.
Desvenlafaxine Desvenlafaxine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Desvenlafaxine.
Flecainide Flecainide The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Flecainide.
Rufinamide Rufinamide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Rufinamide.
Midazolam Midazolam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Midazolam.
Naltrexone Injection Naltrexone Injection The risk or severity of adverse effects can be increased when Doxylamine is combined with Naltrexone.
Milnacipran Milnacipran Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Milnacipran.
Sodium Phosphate Sodium Phosphate The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Doxylamine.
Fesoterodine Fesoterodine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
Degarelix Injection Degarelix Injection The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Degarelix.
Betaxolol Betaxolol The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Betaxolol.
Iloperidone Iloperidone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.
Lacosamide Lacosamide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lacosamide.
Dronedarone Dronedarone The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Dronedarone.
AbobotulinumtoxinA Injection AbobotulinumtoxinA Injection Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.
Palonosetron Injection Palonosetron Injection Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Palonosetron.
Telavancin Injection Telavancin Injection The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Telavancin.
Romidepsin Injection Romidepsin Injection The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Romidepsin.
Tapentadol Tapentadol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.
Pazopanib Pazopanib The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Pazopanib.
Asenapine Asenapine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Asenapine.
Vigabatrin Vigabatrin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.
Oxymorphone Oxymorphone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.
Eribulin Injection Eribulin Injection The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Eribulin.
IncobotulinumtoxinA Injection IncobotulinumtoxinA Injection Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.
Lurasidone Lurasidone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.
Vilazodone Vilazodone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Vilazodone.
Terbutaline Injection Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Doxylamine.
Rilpivirine Rilpivirine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Rilpivirine.
Triptorelin Injection Triptorelin Injection The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Triptorelin.
Vandetanib Vandetanib The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Vandetanib.
Clobazam Clobazam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clobazam.
Vemurafenib Vemurafenib The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Vemurafenib.
Crizotinib Crizotinib The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Crizotinib.
Cabergoline Cabergoline Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cabergoline.
Ezogabine Ezogabine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.
Mirabegron Mirabegron The risk or severity of urinary retention can be increased when Doxylamine is combined with Mirabegron.
Linaclotide Linaclotide The therapeutic efficacy of Linaclotide can be decreased when used in combination with Doxylamine.
Bedaquiline Bedaquiline The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Bedaquiline.
Pomalidomide Pomalidomide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
Dabrafenib Dabrafenib The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Dabrafenib.
Levomilnacipran Levomilnacipran Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.
Vortioxetine Vortioxetine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.
Perampanel Perampanel Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Perampanel.
Droxidopa Droxidopa The therapeutic efficacy of Droxidopa can be increased when used in combination with Doxylamine.
Ceritinib Ceritinib The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ceritinib.
Eslicarbazepine Eslicarbazepine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine.
Suvorexant Suvorexant Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Methamphetamine Methamphetamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Metamfetamine.
Tasimelteon Tasimelteon Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.
Risperidone Injection Risperidone Injection Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Risperidone.
Lenvatinib Lenvatinib The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Lenvatinib.
Panobinostat Panobinostat The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Panobinostat.
Haloperidol Injection Haloperidol Injection Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Ivabradine Ivabradine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ivabradine.
Flibanserin Flibanserin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.
Brexpiprazole Brexpiprazole Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.
Ziprasidone Injection Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ziprasidone.
Cariprazine Cariprazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cariprazine.
Eluxadoline Eluxadoline The risk or severity of constipation can be increased when Doxylamine is combined with Eluxadoline.
Brivaracetam Injection Brivaracetam Injection Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Brivaracetam.
Midodrine Midodrine The risk or severity of Tachycardia can be increased when Midodrine is combined with Doxylamine.
Pimavanserin Pimavanserin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pimavanserin.
Diphenhydramine Injection Diphenhydramine Injection Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.
Ribociclib Ribociclib The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ribociclib.
Doxepin (Insomnia) Doxepin (Insomnia) Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Plecanatide Plecanatide The therapeutic efficacy of Plecanatide can be decreased when used in combination with Doxylamine.
Deutetrabenazine Deutetrabenazine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Deutetrabenazine.
Safinamide Safinamide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Safinamide.
Delafloxacin Delafloxacin The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Delafloxacin.
Tetrabenazine Tetrabenazine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Tetrabenazine.
Buprenorphine Injection Buprenorphine Injection Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Lofexidine Lofexidine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lofexidine.
Eliglustat Eliglustat The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Eliglustat.
Encorafenib Encorafenib The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Encorafenib.
Ivosidenib Ivosidenib The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ivosidenib.
Cannabidiol Cannabidiol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cannabidiol.
Stiripentol Stiripentol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.
Gilteritinib Gilteritinib The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Gilteritinib.
Glasdegib Glasdegib The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Glasdegib.
Prucalopride Prucalopride The therapeutic efficacy of Prucalopride can be decreased when used in combination with Doxylamine.
Magnesium Citrate Magnesium Citrate The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Doxylamine.
Brexanolone Injection Brexanolone Injection Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Brexanolone.
Solriamfetol Solriamfetol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Solriamfetol.
Triclabendazole Triclabendazole The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Triclabendazole.
Entrectinib Entrectinib The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Entrectinib.
Pitolisant Pitolisant The therapeutic efficacy of Pitolisant can be decreased when used in combination with Doxylamine.
Lefamulin Lefamulin Lefamulin may increase the QTc-prolonging activities of Doxylamine.
Phenytoin Injection Phenytoin Injection Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.
Fosphenytoin Injection Fosphenytoin Injection Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.
Lumateperone Lumateperone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lumateperone.
Lasmiditan Lasmiditan Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lasmiditan.
Lemborexant Lemborexant Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lemborexant.
Fenfluramine Fenfluramine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fenfluramine.
Fostemsavir Fostemsavir The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Fostemsavir.
Octreotide Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Doxylamine.
Relugolix Relugolix The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Relugolix.
Viloxazine Viloxazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Viloxazine.
Trazodone Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Doxylamine.
Phenobarbital Phenobarbital Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.
Metaxalone Metaxalone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.
Levorphanol Levorphanol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.
Primidone Primidone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Primidone.
Methsuximide Methsuximide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.
Diethylpropion Diethylpropion Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Diethylpropion.
Chlorpromazine Chlorpromazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.
Diazepam Diazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Diazepam.
Oxazepam Oxazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.
Flurazepam Flurazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.
Clorazepate Clorazepate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clorazepic acid.
Lorazepam Lorazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.
Amantadine Amantadine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Amantadine.
Meprobamate Meprobamate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.
Chlordiazepoxide Chlordiazepoxide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.
Bromocriptine Bromocriptine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Bromocriptine.
Metaproterenol Metaproterenol The risk or severity of Tachycardia can be increased when Doxylamine is combined with Orciprenaline.
Tranylcypromine Tranylcypromine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.
Phenelzine Phenelzine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenelzine.
Procarbazine Procarbazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Procarbazine.
Ergoloid Mesylates Ergoloid Mesylates Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ergoloid mesylate.
Minocycline Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.
Prochlorperazine Prochlorperazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
Thioridazine Thioridazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.
Trifluoperazine Trifluoperazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.
Oxycodone Oxycodone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.
Methadone Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Doxylamine.
Oxybutynin Oxybutynin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.
Benztropine Benztropine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.
Maprotiline Maprotiline Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Trihexyphenidyl Trihexyphenidyl Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
Orphenadrine Orphenadrine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Perphenazine Perphenazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.
Fluphenazine Fluphenazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
Phentermine Phentermine Phentermine may decrease the sedative and stimulatory activities of Doxylamine.
Amoxapine Amoxapine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.
Mechlorethamine Mechlorethamine The therapeutic efficacy of Doxylamine can be decreased when used in combination with Mechlorethamine.
Pyridostigmine Pyridostigmine The therapeutic efficacy of Doxylamine can be decreased when used in combination with Pyridostigmine.
Carbamazepine Carbamazepine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
Molindone Molindone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Molindone.
Clonidine Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Doxylamine.
Clonazepam Clonazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.
Loperamide Loperamide The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Loperamide.
Promethazine Promethazine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.
Digoxin Digoxin The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Digoxin.
Loxapine Loxapine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Loxapine.
Chloroquine Chloroquine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Chloroquine.
Quinine Quinine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Quinine.
Ethosuximide Ethosuximide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
Lactulose Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Doxylamine.
Chlorothiazide Chlorothiazide The serum concentration of Chlorothiazide can be increased when it is combined with Doxylamine.
Chlorthalidone Chlorthalidone The serum concentration of Chlorthalidone can be increased when it is combined with Doxylamine.
Metolazone Metolazone The serum concentration of Metolazone can be increased when it is combined with Doxylamine.
Secobarbital Secobarbital Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.
Desipramine Desipramine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
Amitriptyline Amitriptyline Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
Imipramine Imipramine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Quinidine Quinidine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Quinidine.
Procainamide Procainamide The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Procainamide.
Disopyramide Disopyramide The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Disopyramide.
Valproic Acid Valproic Acid Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.
Tamoxifen Tamoxifen The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Tamoxifen.
Butabarbital Butabarbital Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
Glucagon Injection Glucagon Injection Doxylamine may increase the gastrointestinal motility reducing activities of Glucagon.
Cyclobenzaprine Cyclobenzaprine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
Baclofen Baclofen Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Baclofen.
Cyproheptadine Cyproheptadine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
Clemastine Clemastine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clemastine.
Chlorpheniramine Chlorpheniramine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorpheniramine.
Brompheniramine Brompheniramine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.
Meclizine Meclizine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Meclizine.
Methyclothiazide Methyclothiazide The serum concentration of Methyclothiazide can be increased when it is combined with Doxylamine.
Hydrochlorothiazide Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Hydrochlorothiazide.
Dantrolene Dantrolene Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
Chlorzoxazone Chlorzoxazone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.
Carisoprodol Carisoprodol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.
Methocarbamol Methocarbamol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.
Disulfiram Disulfiram The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Disulfiram.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Propranolol.
Nortriptyline Nortriptyline Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
Butorphanol Injection Butorphanol Injection Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.
Nalbuphine Injection Nalbuphine Injection Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.
Oxytocin Injection Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Doxylamine.
Trimethobenzamide Trimethobenzamide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Trimethobenzamide.
Flavoxate Flavoxate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Papaverine Papaverine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Papaverine.
Fluorouracil Injection Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Fluorouracil.
Acetazolamide Acetazolamide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Acetazolamide.
Ketoconazole Ketoconazole The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ketoconazole.
Pyrantel Pyrantel Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pyrantel.
Thiotepa Injection Thiotepa Injection The therapeutic efficacy of Doxylamine can be decreased when used in combination with Thiotepa.
Isoxsuprine Isoxsuprine The risk or severity of Tachycardia can be increased when Doxylamine is combined with Isoxsuprine.
Hydroxyzine Hydroxyzine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Hydroxyzine.
Thiothixene Thiothixene Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.
Alprazolam Alprazolam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.
Temazepam Temazepam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
Triazolam Triazolam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Triazolam.
Dicyclomine Dicyclomine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine Hyoscyamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Propantheline Propantheline Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Diltiazem Diltiazem The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Diltiazem.
Nifedipine Nifedipine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Nifedipine.
Timolol Timolol The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Timolol.
Pindolol Pindolol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pindolol.
Cisplatin Injection Cisplatin Injection The therapeutic efficacy of Doxylamine can be decreased when used in combination with Cisplatin.
Indapamide Indapamide The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Indapamide.
Pentamidine Injection Pentamidine Injection The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Pentamidine.
Labetalol Labetalol The risk or severity of Tachycardia can be increased when Doxylamine is combined with Labetalol.
Leuprolide Injection Leuprolide Injection The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Leuprolide.
Guanabenz Guanabenz The risk or severity of Tachycardia can be increased when Doxylamine is combined with Guanabenz.
Pimozide Pimozide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pimozide.
Amiodarone Amiodarone The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Amiodarone.
Ciprofloxacin Ciprofloxacin The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ciprofloxacin.
Fluoxetine Fluoxetine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.
Nimodipine Nimodipine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Nimodipine.
Clozapine Clozapine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clozapine.
Estazolam Estazolam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Estazolam.
Ofloxacin Ofloxacin The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ofloxacin.
Clarithromycin Clarithromycin The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Clarithromycin.
Felodipine Felodipine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Felodipine.
Itraconazole Itraconazole The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Itraconazole.
Sotalol Sotalol The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Sotalol.
Zolpidem Zolpidem Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Isradipine Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Doxylamine.
Cisapride Cisapride Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cisapride.
Gabapentin Gabapentin Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.
Venlafaxine Venlafaxine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Venlafaxine.
Nizatidine Nizatidine The therapeutic efficacy of Doxylamine can be decreased when used in combination with Nizatidine.
Fluvoxamine Fluvoxamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.
Nefazodone Nefazodone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nefazodone.
Lamotrigine Lamotrigine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.
Losartan Losartan The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Losartan.
Tramadol Tramadol Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tramadol.
Moexipril Moexipril The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Moexipril.
Nicardipine Nicardipine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.
Bupropion Bupropion Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Bupropion.
Saquinavir Saquinavir The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Saquinavir.
Riluzole Riluzole Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Riluzole.
Ritonavir Ritonavir The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ritonavir.
Clomipramine Clomipramine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.
Mirtazapine Mirtazapine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Topiramate Topiramate Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
Pramipexole Pramipexole Doxylamine may increase the sedative activities of Pramipexole.
Donepezil Donepezil Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Donepezil.
Nelfinavir Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Doxylamine.
Azithromycin Azithromycin The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Azithromycin.
Loratadine Loratadine Doxylamine may increase the anticholinergic activities of Loratadine.
Selegiline Selegiline Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Selegiline.
Sertraline Sertraline Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sertraline.
Propafenone Propafenone The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Propafenone.
Ropinirole Ropinirole Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ropinirole.
Quetiapine Quetiapine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.
Cetirizine Cetirizine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.
Paroxetine Paroxetine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Paroxetine.
Tolcapone Tolcapone Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.
Citalopram Citalopram Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Citalopram.
Efavirenz Efavirenz Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.
Tolterodine Tolterodine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.
Thalidomide Thalidomide Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Galantamine Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Doxylamine.
Levetiracetam Levetiracetam Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists